D-0034-2018 Class III Terminated

Recalled by AbbVie Inc. — North Chicago, IL

FDA drug recall D-0034-2018 was initiated by AbbVie Inc. on Sep 8, 2017 and is designated Class III. Reason for recall: Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions. The recall status is terminated (terminated Apr 23, 2018). Affected quantity: 48 cartons (30 foil packets per carton).

Recall details

Product Type
Drugs
Report Date
Nov 1, 2017
Initiation Date
Sep 8, 2017
Termination Date
Apr 23, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
48 cartons (30 foil packets per carton)

Product description

AndroGel (testosterone gel) 1.62%, 40.5mg in 2.5g aluminum foil packet, 30 Packets per carton. Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064 USA. NDC: 0051-8462-30

Reason for recall

Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.

Distribution pattern

AZ

Code information

Lot: D60010A, EXP. 01/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0034-2018
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for AbbVie Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0034-2018. Report a data issue: hello@regdatalab.com.